Skip to main
DWTX

DWTX Stock Forecast & Price Target

DWTX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Dogwood Therapeutics is expected to have a positive outlook in 2026, with the upcoming Phase 2b results for Halneuron in chemotherapy induced neuropathic pain (CINP) being a major catalyst. The lack of approved drugs for this indication provides a significant market opportunity for Dogwood, and further success in other pain indications could expand Halneuron's potential. In addition, the initiation of the SP16 clinical program and potential partnerships for legacy assets could provide further upside for the stock.

Bears say

Dogwood Therapeutics is a pre-revenue, development-stage biopharmaceutical company with a focused pipeline targeting chronic neuropathic pain and neuropathy. Despite the upcoming initiation of a Phase 1b study for SP16 targeting breast cancer patients, the lack of revenue and the novel mechanism of action for the drug raise concerns about the company's future success. In addition, initial results for the study are not expected until early-2027, delaying any potential positive developments for the stock.

DWTX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dogwood Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dogwood Therapeutics, Inc. (DWTX) Forecast

Analysts have given DWTX a Strong Buy based on their latest research and market trends.

According to 1 analysts, DWTX has a Strong Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dogwood Therapeutics, Inc. (DWTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.